Page 1,094«..1020..1,0931,0941,0951,096..1,1001,110..»

Category Archives: Transhuman News

Celeste is on track for her first number one album this week – NME

Posted: February 2, 2021 at 7:25 pm

Celeste is on course to securing her first UK number one album this week with her debut LP Not Your Muse.

The artist,who won the BBCs Sound Of 2020 poll and the BRIT Awards Rising Star prize last year, released her debut album last week.

According to the Official Charts Company, Celeste commanded a lead of 8,000 sales yesterday (February 1) after Not Your Muse racked up the most physical and digital sales over the weekend.

Celeste is currently holding off Steven Wilsons The Future Bites and Arlo Parksdebut Collapsed In Sunbeams, which respectively occupy the two other positions in the current top three.

This weeks final UK albums chart will be announced on Friday afternoon (February 5), with Bring Me The Horizon who bagged the UKs number one album last week with their October-released EP Post Human: Survival Horror set to relinquish their grip of the top spot.

Earlier this week Celeste announced a UK tour for spring 2022 in support of Not Your Muse. Shes also set to play a trio of gigs in London in the summer.

You can see Celestes 2022 tour dates below.

March 202231 O2 Institute, Birmingham

April 20223 O2 Academy, Bristol7 Barrowland Ballroom, Glasgow12 Corn Exchange, Cambridge16 Albert Hall, Manchester21 Roundhouse, London

Read more:
Celeste is on track for her first number one album this week - NME

Posted in Post Human | Comments Off on Celeste is on track for her first number one album this week – NME

In the name of cricket sex, humans need to stop making noise – KNBR

Posted: at 7:25 pm

We humans tend to spread and frolic about wherever we please, a development that has been found to harm animals environments and health, and therefore ultimately our own. That may be the effect on crickets because of our constant noisemaking from traffic and other activities.

The mating behavior of crickets may be significantly affected by those sounds, according to a study published Monday in the journal Behavioral Ecology.

The reproduction of field crickets is important to the worlds of plants, humans and animals. Because field crickets eat lots of plant materials rich in cellulose, their fecal matter is easily decomposed by bacteria and fungi.

Their activity, then, greatly accelerates the energy and nutrient flows in an ecosystem and provides plants with a much more abundant reservoir of highly available, essential growth factors, according to a Penn State New Kensington blog post.

Field crickets diets also help to manage weed growth on both natural and human-made ecosystems. Additionally, crickets are essential food sources for some birds and other animals that have crucial roles in providing our food, timber, medicine and recreation.

Humans are continually changing the characteristics of environments, including through the production of anthropogenic noise, said study coauthor Sophie Mowles, a senior lecturer in animal and environmental biology at Anglia Ruskin University in England, in a news release.

As mate choice is a powerful driving force for evolution through sexual selection, disruptions may cause a decline in population viability. And because anthropogenic noise is a very recent evolutionary selection pressure, it is difficult to predict how species may adapt.

Male crickets have an innate playlist of songs from which to choose to attract potential mates: The calling song attracts the female, then the courtship, or mating, song induces the female to mate. A fighting chirp sends warnings to other male suitors. And what both sexes need for all these things to happen are highly sensitive organs on their forelegs, so that they can receive sound.

To assess the effects of environmental changes, the researchers paired female crickets with silenced male crickets in ambient noise conditions, artificial white noise settings and recorded traffic noise conditions.

The researchers allowed the males to court the females, and when the males tried to sing their mating tunes, the researchers played artificial courtship songs that ranged from low- to high-quality.

When induced to mate by a high-quality courtship song amid ambient noise, female crickets mounted the males sooner and more often. But when those crickets were subjected to white noise and traffic sounds conditions, the quality of the mating song didnt help the frequency and duration of females mating with males, the study said.

Traffic noise and the crickets courtship song do not share similar acoustic frequencies, so rather than masking the courtship song, we think the traffic noise serves as a distraction for the female cricket, said lead author Adam Bent, who led the study as part of his doctoral program at Anglia Ruskin University, in a news statement.

Mating songs are labor-intensive; they require male crickets to expend a lot of energy and therefore hold key details about the males qualities, the study said so human-made noise may have changed how the females perceived the males when deciding on a mate. This blurring also could affect male crickets health if they work to produce a more impressive mating song, and therefore those crickets survival, too.

At the same time, female crickets may choose to mate with a lower-quality male as they are unable to detect differences in mate quality due to the man-made noise, Bent added, and this may lead to a reduction or complete loss of offspring viability.

Here is the original post:
In the name of cricket sex, humans need to stop making noise - KNBR

Posted in Post Human | Comments Off on In the name of cricket sex, humans need to stop making noise – KNBR

Bring Me The Horizon frontman Oli Sykes lived with monks in rural Brazil to get out of very dark place – The Scottish Sun

Posted: at 7:24 pm

BRING Me The Horizon frontman Oli Sykes has revealed he spiralled into a very dark place during lockdown but credits going to live with monks in rural Brazil for perking him up again.

The singer, 34, whose band is at No1 in the album charts with Post Human: Survival Horror, said he went on a spiritual rehab by staying in a Hindu ashram with his wife, Brazilian model Alissa Salls.

9

In an exclusive chat, he said: For a while I just went into a very dark place, a place that Ive been in before, but it was the start of a beautiful thing finding myself again.

I think everyone experienced some level of this during lockdown. Even the most positive of people cant hide from the fact that these are very dark times.

It was depression for me, for sure, but that worst kind of depression where its not like youre feeling sad but where youre feeling nothing at all. Youre really just out of touch with your own emotions.

A couple of hours from where Alissas family lives theres actually an ashram, a Hare Krishna ashram, and they invited us to go and stay there.

9

So for the best part of a month we went and lived on an ashram, without all our devices and disconnected and basically lived as if we were Hare Krishna for a month.

We woke up at five in the morning and prayed to Krishna and sang and danced, to just connect with who we are.

And these people are just the happiest people in the world, these monks, you go and meet them and theyre the most positive and spiritual people, and I just thought, I want a piece of that. I want to see what its like.

In 2014, Oli found himself in dark times and was admitted to rehab for a Ketamine addiction.

9

But the singer believes living on the ashram is the best kind of therapy you can get.

He added: It was like a rehab to be honest. I went to rehab a few years ago for drugs.

But when I came here it was a detox, but from everything emotional issues, dependency on devices, dependency on being a musician.

I just learned how to be still and wake up and think Ive got nothing to do today and thats absolutely fine.

9

The songwriter has long been an outspoken atheist and has penned blasphemous lyrics.

But the musician now sees religion in a new light after staying at the monastery.

He said: There were definitely a lot of questions I had for myself when I was there.

I almost felt bad because I thought, if the main guru knew some of the songs I sing about God, would they want me here? I spoke to the guru and I voiced these concerns.

9

I said to him I really like your principles and the way you look at stuff. They believe youre serving God, so whatever comes your way will happen, you should just be happy and blessed by it and not always wanting more.

I said I really like that concept and I could use that in my life to be happier.Its the organised system of religion I have a problem with, the way it divides people.

But now on a spiritual level I think its really important to believe in something higher and bigger than yourself.

The band topped the album charts for a second time last Friday, which came as a shock to the rocker.

9

In recent years, the charts have been dominated by rap and hip hop music, but Oli believes the pandemic may be the catalyst for a resurgence of rock music.

He said: Its just trends. In the early 2000s rock was pop music, and now its hip hop and house music. It comes around in waves.

And theres no doubt in my mind that at some point rock is going to be the biggest thing in the world again.

At some point people crave raw emotion. Its just reflective of the times and I kind of had this feeling. I feel that rock music was born out of depressive times with the Beatles coming after the world wars.

9

The thing is with coronavirus, maybe people have stopped connecting as much with rappers singing about expensive cars and living in The Hills and people might be like, well that doesnt mean anything to me anymore.

Im going through these hard, dark times, I need to listen to people talking about that. I think out of this the rock scene will get bigger again.

Yorkshireman Oli isnt the only rock frontman to have come out of hometown Sheffield.

He went to Stocksbridge High School then Barnsley College alongside indie band Arctic Monkeys and lead singer Alex Turner - who were in the year above Oli at the time.

9

And the musician says he would love to collaborate with his Sheffield schoolmates some time.

He shared: A couple of years ago we were at a festival and Alex was playing and I just walked into the backstage area, the VIP bit where people are having drinks, and he just saw me out the corner of his eye and went, 'Wahey, Ive been waiting years for this!'

9

He ran up to me and gave me a big bear hug and I was so taken aback like what the f*** just happened. And he was like Ive watched all your videos on YouTube, hows it going

Exclusive

ORA & OUTRita Ora splits from boyfriend Romain Gavras after lockdown forces them apart

Exclusive

SKATE IT OFFDOI bosses warn stars if they test positive for Covid theyre out of the show

Exclusive

SHOW ON HOLL-DHolly Willoughby's new TV show The Real Games cancelled over Covid concerns

Exclusive

WAG CLAUSERebekah Vardy's key demand to avoid Wagatha Christie court showdown with Coleen

Exclusive

KISS HUGHESLove Island's Chris Hughes dating stunning model after Jesy Nelson heartbreak

'FINAL STRAW'Sheridan Smith 'almost died' after Graham Norton humiliated her at the Baftas

I mean, he was a bit merry, but I couldnt believe it. Hes in one of the biggest bands in the world, and fair enough we went to school together, but I just did not see that coming. It was a super cool moment.

I would love to do something with them, collaborate somehow. Because it is just a sick thing that we both went to the same school and both did well.

Theyve been an inspiration to my band, we watched how they did stuff and we took a lot of notes. So it would be super cool to do something with them at some point.

See original here:
Bring Me The Horizon frontman Oli Sykes lived with monks in rural Brazil to get out of very dark place - The Scottish Sun

Posted in Post Human | Comments Off on Bring Me The Horizon frontman Oli Sykes lived with monks in rural Brazil to get out of very dark place – The Scottish Sun

Rupesh Mahore commit this 23-year-old NIT Rourkela student’s name to memory as he is going to take Astrophysics by storm – EdexLive

Posted: at 7:24 pm

Somewhere between being enraptured by Physics and developing an inclination for Astrophysics,Rupesh Mahorediscovered his purpose. And the fact that in his very first year at NIT Rourkela he started getting involved in small research projects gave his research ambitions a bigger boost. From the Department of Nanotech at IIT Guwahati to Bhabha Atomic Research Centre (BARC) in Kolkata, he was already finding as much work as he could. But it was when he was interning with ISRO for the Chandrayaan-2 mission that he was left wide-eyed with wonder. "I was at the launch site of Chandrayaan-2 and I felt the propulsion of the craft in the atmosphere. It was a different kind of energy altogether," says the 23-year-old in an attempt to describe that palpable feeling that drives him every day. Feeding off this feeling, he joined hands with friendsGunendra MahoreandShantanu Koreto launch the start-upSpacegrade Incin October 2019 in their quest to develop solutions for space technology with the power of AI and ML.

Here's is where we should mention the Planck Physics Society started by Rupesh and Shantanu under which they organise guest lectures at NIT. The most successful one they have organised was with Gabe Gabriel, former Engineer Programmer for the Kennedy Space Centre, NASA. "It was a wonderful event with people not just from our institute but also from DRDO and other parts of Rourkela attending," says the youngster who is pursuing a five-year Integrated MSc in Physics and is currently in his fourth year. Actually, it was in another discussion with Gabriel that he encouraged students to work on AI and ML-assisted projects for space applications.

They are working on three projects now, one more exciting than the other. Keep reading and you'll see for yourself.

Sweeping through spaceDead satellites, orbiters shredded into pieces are just the beginning of the debris floating around in space at this very moment. It actually poses a monumental problem and Rupesh tells us why. "They travel at the speed of 20,000 km per hour and that could harm existing satellites and missions," says the youngster. And where there is a problem, there is scope for a solution. Thus, they joined forces with Hyoristic Innovations, a space start-up based out of Chennai, providing Research and Development support for debris mitigation. It's all about tracking the different sizes of debris and capturing them.

Working within limitsWith spacecrafts, there is always the limitation of space, volume restriction to be specific. There are all kinds of fluids, gases and lubricants that need to be supplied from one part of the craft to another and for this, tiny micropumps or micro propulsions are required. Hence, they are designing PZT-actuated micropumps for space application and these, we are told, are as small as a coin. "When we pass electricity or voltage through it, it creates a pumping action," explains Rupesh. Their preliminary research work was accepted at the International Conference on Nano and Materials Science 2021 at Georgia Tech and IEEE-ICEE 2020 at IIT Delhi.

Which solution would you choose?Last year, when ISRO issued a clarion call that it was accepting proposals for 17 topics for its next mission, the team at Spacegrade Inc knew that they had to jump right into it. And with the help of Prof RK Biswal from the Department of Humanity Sciences at NIT Rourkela, they have taken up the psychological tests that the astronaut goes through pre, during and post human spaceflights. "For example, during the test, based on their facial expression during the isolation and confinement phases, we try to test how they are doing. And after, we test the ill effects of the flight," informs Rupesh. With the help of the only Indian who has been to space, Rakesh Sharma, they have already started working on this project last month.

Go Corona, go!With regards to the COVID crisis specifically, the team designed a Hexafunctional Autonomous Robotic Cart (HARC) which can be remotely controlled and can perform up to six functions, like delivering medicines and taking someone's temperature. They presented a paper on this at the International Conference on Robotics and Artificial Intelligence at IIT Madras in December 2020 and supplied the device to a few hospitals in and around Rourkela.

For more o him, check outlinkedin.com/in/rupesh-mahore-83499712a/

Read the rest here:
Rupesh Mahore commit this 23-year-old NIT Rourkela student's name to memory as he is going to take Astrophysics by storm - EdexLive

Posted in Post Human | Comments Off on Rupesh Mahore commit this 23-year-old NIT Rourkela student’s name to memory as he is going to take Astrophysics by storm – EdexLive

Bring Me The Horizon Tickets For New Hull Bonus Arena Show On Sale 12pm Today – Stereoboard

Posted: at 7:24 pm

Monday, 01 February 2021 Written by Jon Stickler

Bring Me The Horizon have added a Hull show to their Post Human Tour. Bring Me The Horizon tickets go on general sale at 12pm today.

The Sheffield quintet will take over the Bonus Arena on September 20, prior to previously confirmed stops in Glasgow, Cardiff, Sheffield, Birmingham and London, where they'll play the O2 Arena. Tickets for those dates are already on sale.

In January, the band announced three intimate instore shows; twoat Pryzm in Kingston on September 16 and one at Liverpool's Mountford Hall on September 18.

The low profile performances will see the band play their 2020'Post Human: Survival Horror' EP in its entirety for the first time. Remaining tickets are on sale now.

Bring Me The Horizon Upcoming Tour Dates are as follows

Compare & Buy Bring Me The Horizon Tickets at Stereoboard.com.

Let Us Know What You Think - Leave A Comment!

Wed 27 Jan 2021

Bring Me The Horizon Announce Intimate Instore Shows For September

Thu 21 Jan 2021

Bring Me The Horizon Add Hull Bonus Arena Show To Post Human Tour - How To Buy Tickets

Fri 18 Dec 2020

Bring Me The Horizon Post 'Live At The Royal Albert Hall' To Streaming Services

Mon 09 Nov 2020

Bring Me The Horizon - POST HUMAN: SURVIVAL HORROR (Album Review)

Fri 23 Oct 2020

Bring Me The Horizon Tickets For Post Human UK Arena Tour On Sale 10am Today

View original post here:
Bring Me The Horizon Tickets For New Hull Bonus Arena Show On Sale 12pm Today - Stereoboard

Posted in Post Human | Comments Off on Bring Me The Horizon Tickets For New Hull Bonus Arena Show On Sale 12pm Today – Stereoboard

Govt suspends Internet, fortifies sites and chokes supplies to stifle farmers unrest, but it wont deter them – National Herald

Posted: at 7:24 pm

The Delhi Police, on its part, took recourse to literally picking up a freelance journalist involved in exposing the fact that a group of locals who had managed to simply walk in and attack the peacefully protesting farmers at Singhu border, leading to violence, were in fact outsiders apparently deployed to create mischief from the site on Saturday evening.

The journalist, Mandeep Punia, was thereafter untraceable, only to be produced before a magistrate on Sunday, and summarily remanded to judicial custody in Tihar jail for 14 days, without the presence of a defence lawyer.

Punias wife later revealed that while the journalist was slated to appear before the court at 2 pm, the police ushered him in within the court premises at 1:30 pm, causing the proceedings to begin even before the scribes lawyers could arrive.

According to the FIR against Punia, a group of protesters tried to break the barricades at Singhu border and after they were stopped, one person got into a scuffle with a constable and started to drag the latter towards the protest site, referring to Punia. It claimed that three policemen were injured in the scuffle.

The event triggered a huge outcry on social media and among members of civil society, but it remains to be seen if the journalist manages to secure bail.

More here:
Govt suspends Internet, fortifies sites and chokes supplies to stifle farmers unrest, but it wont deter them - National Herald

Posted in Post Human | Comments Off on Govt suspends Internet, fortifies sites and chokes supplies to stifle farmers unrest, but it wont deter them – National Herald

Bristol Myers’ psoriasis drug strikes again, beating Amgen’s Otezla in a 2nd pivotal trial – FierceBiotech

Posted: at 7:10 pm

Chalk another one up for Bristol Myers Squibbs psoriasis drugthe TYK2 inhibitor outshone placebo and Amgens Otezla in a second phase 3 study, teeing up discussions with regulators.

The study, known as POETYK PSO-2, tested the drug, deucravacitinib, against placebo and Otezla in 1,020 patients with moderate to severe plaque psoriasis, the company said in a statement. After 16 weeks of treatment, significantly more patients taking Bristol Myers drug than placebo had a 75% reduction of psoriasis area and severity and clear or almost clear skin as measured by the static Physicians Global Assessment, a visual assessment of psoriasis.

In addition to meeting these co-primary endpoints, deucravacitinib also beat Otezla on these measures, hitting key secondary endpoints.

Blazing a Trail to Clinical Trial Diversity: Four-Part Webinar Series from Syneos Health, Featuring Pharma, Clinical Research and Community Health Leaders

This series will identify obstacles that stifle appropriate patient diversity in trials; unpack the organizational overhaul needed; share how sponsors, patients & investigators have come together to overcome hurdles; and explore how policy innovations can move the industry forward.

RELATED: Bristol Myers' psoriasis drug beats Amgen rival in phase 3

The company reported the results in broad strokes with plans to present detailed data at a future medical meeting. The news comes three months after Bristol Myers reported a similar performance in the 666-patient POETYK PSO-1 study, in which deucravacitinib also outperformed placebo and Otezla.

The superior efficacy we have observed in patients with moderate to severe psoriasis, combined with the well-tolerated safety profile, are consistent with the novel mechanism of action of deucravacitinib, a potential new class of molecule, said Samit Hirawat, M.D., chief medical officer of Bristol Myers Squibb.

Deucravacitinib works by blocking TYK2, an enzyme involved in the IL-12, IL-12 and type 1 IFN pathways, which play a role in psoriasis and other immune-mediated diseases. Bristol Myers is developing the drug for psoriatic arthritis, lupus and inflammatory bowel disease.

Read the original post:
Bristol Myers' psoriasis drug strikes again, beating Amgen's Otezla in a 2nd pivotal trial - FierceBiotech

Posted in Psoriasis | Comments Off on Bristol Myers’ psoriasis drug strikes again, beating Amgen’s Otezla in a 2nd pivotal trial – FierceBiotech

Skin Infections in Early Childhood Linked to Pediatric Psoriasis – HealthDay News

Posted: at 7:10 pm

TUESDAY, Feb. 2, 2021 (HealthDay News) -- Skin infections in the first two years of life are associated with pediatric psoriasis, according to a study recently published in the Journal of the American Academy of Dermatology.

Yi-Ju Chen, M.D., Ph.D., from Taichung Veterans General Hospital in Taipei, Taiwan, and colleagues conducted a nationwide nested case-control study to examine the impact of infantile infection and antibiotic exposure on pediatric psoriasis development. A total of 1,527 patients with pediatric psoriasis were identified and matched with 15,270 control individuals without psoriasis.

The researchers found that in both groups, the mean age was 9.9 3.7 years. In a multivariate analysis, independent associations with pediatric psoriasis were seen for atopic dermatitis (adjusted odds ratio, 2.07) and a family history of psoriasis, especially for the mother (adjusted odds ratio, 9.86) or other first-degree relatives (adjusted odds ratio, 5.49). Significant associations with pediatric psoriasis were seen for skin viral and bacterial infections (adjusted odds ratio, 1.35) and fungal infections (adjusted odds ratio, 1.71) in the first two years of life. No correlation was seen for systemic antibiotic exposure.

"Our results suggest that skin and fungal infections in early life are associated with pediatric psoriasis development," the authors write. "The role of early-life microbiota dysbiosis in the pathogenesis of pediatric psoriasis might be worth further investigation."

Abstract/Full Text (subscription or payment may be required)

Continue reading here:
Skin Infections in Early Childhood Linked to Pediatric Psoriasis - HealthDay News

Posted in Psoriasis | Comments Off on Skin Infections in Early Childhood Linked to Pediatric Psoriasis – HealthDay News

Arcutis Announces Positive Topline Results from Pivotal DERMIS-1 and -2 Phase 3 Trials of Topical Roflumilast Cream (ARQ-151) in Plaque Psoriasis -…

Posted: at 7:10 pm

WESTLAKE VILLAGE, Calif., Feb. 01, 2021 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a medical dermatology company developing innovative treatments for patients with immune-mediated dermatological diseases and conditions, today announced positive topline results from the DERMIS-1 and DERMIS-2 pivotal Phase 3 studies evaluating roflumilast cream (ARQ-151) as a potential topical treatment for plaque psoriasis. Roflumilast cream is a once daily topical formulation of roflumilast, a highly potent and selective phosphodiesterase type 4 inhibitor (PDE4).

On the studies primary endpoint of Investigator Global Assessment (IGA) Success at week 8, roflumilast cream 0.3% had an IGA Success rate in DERMIS-1 of 42.4% compared to a vehicle rate of 6.1% (P<0.0001), and in DERMIS-2 an IGA Success rate of 37.5% compared to a vehicle rate of 6.9% (P<0.0001). IGA Success was defined as an IGA score of clear or almost clear and at least a 2-grade improvement from baseline. Roflumilast cream 0.3% also demonstrated statistically significant improvements over vehicle on key secondary endpoints, including on Intertriginous IGA (I-IGA) Success, Psoriasis Area Severity Index-75 (PASI-75), reductions in itch as measured by the Worst Itch-Numerical Rating Scale (WI-NRS), and patient perceptions of symptoms as measured by the Psoriasis Symptoms Diary (PSD).

In DERMIS-1 and DERMIS-2, roflumilast cream was generally safe and well-tolerated. The incidence of Treatment Emergent Adverse Events (TEAEs) was low and similar between active treatment and vehicle, with most TEAEs assessed as mild to moderate in severity. Overall, 90% of patients who were randomized to roflumilast cream in the studies completed the full 8 weeks. Among subjects receiving roflumilast cream, there were only 5 discontinuations in DERMIS-1 due to a TEAE (1.7% of subjects) and 1 discontinution in DERMIS-2 due to TEAE (0.3% of subjects), and there were no treatment-related Serious Adverse Events (SAEs).

We are delighted with the strength of these Phase 3 data, which surpassed the already positive results we saw in our Phase 2 studies, said Patrick Burnett, M.D., Ph.D., FAAD, Arcutis Chief Medical Officer. These data reinforce our conviction that topical roflumilast is exceptionally well suited to address the unmet needs in the topical treatment of psoriasis, offering an ideal combination of efficacy comparable to the results of published clinical studies of high-potency steroid/calcipotriene or high-potency steroid/tazarotene combination products, the ability to use the drug chronically in any anatomical area, and a very favorable safety and tolerability profile. Based on the strength of these Phase 3 data, we anticipate submission of our NDA to the U.S. FDA in the second half of 2021. Importantly, we want to express our appreciation to the trial participants and the clinical investigators for their commitment to this important research effort.

The impact of plaque psoriasis extends beyond the serious physical burdens of the disease, with many patients experiencing adverse psychological and social effects as well, said Mark Lebwohl, MD, Professor and Dean for Clinical Therapeutics, Icahn School of Medicine at Mount Sinai, and participant in the trial. The existing topical treatments prescribed to psoriasis patients have significant shortcomings, which lead to difficult trade-offs between efficacy, safety, and tolerability. These data demonstrate once-daily topical roflumilast cream was well-tolerated and achieved early and significant improvements in psoriasis signs and symptoms, including having a profound impact on itch.

The Trials of PDE4 inhibition with Roflumilast for the Management of plaque PsoriasIS One and Two (or DERMIS-1 and DERMIS-2) were identical Phase 3 randomized, parallel, double-blind, vehicle-controlled, multi-national, multi-center studies in which roflumilast 0.3% cream or matching vehicle cream were applied once daily for 8 weeks to subjects age 2 years and above with mild, moderate or severe chronic plaque psoriasis involving between 2% and 20% body surface area. DERMIS-1 enrolled 439 subjects, and DERMIS-2 enrolled 442 subjects. The primary endpoint of the studies was IGA Success at week 8. Multiple secondary endpoints were also evaluated, including I-IGA Success, and improvements in Psoriasis Area Severity Index (PASI), itch as measured by the WI-NRS and patient perceptions of symptoms as measured by the Psoriasis Symptoms Diary (PSD). The Company anticipates submission of its NDA to the FDA in the second half of 2021.

Management will host a conference call today at 8:30 a.m. EST to discuss these results. To access the call, please dial (833) 614-1393 (domestic) or (914) 987-7114 (international) prior to the scheduled conference call time and provide the conference ID 8079585. A live webcast of the call will be available on the "Investors" section of the company's website, http://www.arcutis.com. An archived version of the webcast will be available on the Arcutis website after the call.

About PsoriasisPsoriasis is a common, non-contagious, immune-mediated skin disease that affects approximately 8.6 million patients in the United States. About 90% of patients develop plaque psoriasis, which is characterized by raised, red areas of skin covered with a silver or white layer of scale. Psoriatic plaques can appear on any area of the body, but most often appear on the scalp, knees, elbows, trunk, and limbs, and are often itchy and sometimes painful. Plaques in certain anatomical areas present particular treatment challenges, including the face, elbows and knees, scalp, and intertriginous regions such as the groin, axillae and inframammary areas.

About Topical Roflumilast Cream

Roflumilast Cream is a topical cream formulation of a highly potent and selective PDE4 inhibitor (roflumilast). Roflumilast has been approved by the U.S. Food and Drug Administration (FDA) for oral treatment to reduce the risk of exacerbations of chronic obstructive pulmonary disease (COPD) since 2011. Roflumilast has shown greater potency (25- to 300-fold) than the two other FDA-approved PDE4 inhibitors. PDE4 is an intracellular enzyme that increases the production of pro-inflammatory mediators and decreases production of anti-inflammatory mediators and has been implicated in a wide range of inflammatory diseases including psoriasis, eczema, and COPD. PDE4 is an established target in dermatology, and other PDE4 inhibitors have been approved by the FDA for the topical treatment of atopic dermatitis or the systemic treatment of plaque psoriasis.

About Arcutis - Bioscience, applied to the skin.

Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatology. The Company is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. Arcutis robust pipeline includes four novel drug candidates currently in development for a range of inflammatory dermatological conditions. The Companys lead product candidate, topical roflumilast, has the potential to become the standard of care for plaque psoriasis, atopic dermatitis, scalp psoriasis, and seborrheic dermatitis. For more information, visit http://www.arcutis.com or follow the company on LinkedIn and Twitter.

Forward Looking StatementsThis press release contains "forward-looking" statements, including, among others, statements regarding roflumilast creams potential as a treatment for plaque psoriasis; and expectations with regard to the timing of potential NDA submission in 2021. These statements involve substantial known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements and you should not place undue reliance on our forward-looking statements. Risks and uncertainties that may cause our actual results to differ include risks inherent in the clinical development process and regulatory approval process, the timing of regulatory filings, and our ability to defend our intellectual property. For a further description of the risks and uncertainties applicable to our business, see the "Risk Factors" section of our Form 10-Q filed with U.S. Securities and Exchange Commission (SEC) on November 5, 2020, as well as any subsequent filings with the SEC. We undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available.

Investors and Media:Heather Rowe ArmstrongVice President, Investor Relations & Corporate Communicationsharmstrong@arcutis.com805-418-5006, Ext. 740

More here:
Arcutis Announces Positive Topline Results from Pivotal DERMIS-1 and -2 Phase 3 Trials of Topical Roflumilast Cream (ARQ-151) in Plaque Psoriasis -...

Posted in Psoriasis | Comments Off on Arcutis Announces Positive Topline Results from Pivotal DERMIS-1 and -2 Phase 3 Trials of Topical Roflumilast Cream (ARQ-151) in Plaque Psoriasis -…

Genital psoriasis: Signs, symptoms, and treatment options – Insider – INSIDER

Posted: at 7:10 pm

Psoriasis is a chronic skin condition that causes red, itchy patches or bumps on the skin. It can develop anywhere on the body, including the genitals. About 63% of adults with psoriasis may experience genital psoriasis at least once in their lifetime.

"Genital psoriasis can occur anywhere on the genitals, but the tip of the penis and in folds of skin are the most common locations," says Jeffrey M. Cohen, MD, assistant professor of dermatology at Yale School of Medicine. It can also affect the crease between the buttocks, skin above the genitals, and inner and upper thigh areas.

There are many ways to treat genital psoriasis, but mild topical corticosteroids are the first line of treatment. Here's how you can recognize, treat, and avoid irritating genital psoriasis.

Genital psoriasis is a form of inverse psoriasis, which commonly occurs in skin folds such as the underarms, under the breasts, and around the genital area.

"[It] generally presents as pink somewhat raised areas. Sometimes, these can be scaly, and other times, they may not be. The spots tend to be itchy, but they can also feel irritated," says Cohen.

Thick, scaly patches called plaques can also appear on the affected area, which are either red with silvery or white buildup (for lighter skin tones) or purple, gray, or dark brown (for darker skin tones). You may experience discomfort, pain, itching, and cracking of the skin.

Treatments for psoriasis vary from one person to another, and some individuals might need a combination of treatments to reduce their symptoms.

Important: Almost 50% of genital psoriasis patients don't discuss symptoms with their physicians due to shyness and fear of judgment, which may result in undertreatment. Genital psoriasis is common in psoriasis patients and is nothing to be ashamed of.

"Studies have shown that for many patients, genital psoriasis interferes with their sex lives, for reasons such as embarrassment or discomfort, but there is no health risk (for either partner) if someone with genital psoriasis has sex," says Cohen.

Genital psoriasis might also be mistaken for eczema or fungal infection. "It is important to note that several skin conditions can look quite similar in the genital region, and a diagnosis of genital psoriasis should be made by a board-certified dermatologist," says Cohen.

Psoriasis develops due to an overreaction of the body's immune response, which causes inflammation. As a result, new skin cells grow too fast and move to the surface, manifesting in reddish and itchy bumps.

Here are some tips to avoid irritation and further discomfort from genital psoriasis:

"Scratching or touching psoriasis cannot cause it to spread from one part of the body to another. It is also important to note that psoriasis is not at all contagious to others," says Cohen.

There are plenty of treatment plans for genital psoriasis, and what works for one person might not work for another. Although it is a chronic condition that reduces the quality of life, proper treatment can improve it.

About 70% to 80% of cases of psoriasis are mild, requiring only topical treatments. They can come in the form of corticosteroids, which are creams and ointments that reduce inflammation when applied to the skin, or nonsteroidal agents, medications that don't contain or are not steroids, like calcineurin inhibitors that suppress the immune system and reduce symptoms.

Biologics, or medications that target specific parts of the immune system, can be very effective for many types of psoriasis and generally come in the form of a pill, injection, or intravenous infusion. "Good moisturizers, such as Vaseline, are also helpful for patients with genital psoriasis," says Cohen.

Psoriasis doesn't go away and is present for someone's entire life. "However, some people experience long periods of time when psoriasis is not active," says Cohen. Following a treatment plan closely can reduce symptoms and avoiding certain irritants can help improve your genital psoriasis.

Genital psoriasis is a chronic skin condition that can develop anywhere on the genitals, buttocks, and thigh areas. Symptoms include red and itchy patches of skin that may or may not be scaly.

To avoid discomfort and irritation, moisturize the affected area and wear breathable underwear. Genital psoriasis is treated with topical medications and biologics (aka medications that target the cause of psoriasis), so talk to your healthcare provider to discuss the best treatment plan for you.

View post:
Genital psoriasis: Signs, symptoms, and treatment options - Insider - INSIDER

Posted in Psoriasis | Comments Off on Genital psoriasis: Signs, symptoms, and treatment options – Insider – INSIDER

Page 1,094«..1020..1,0931,0941,0951,096..1,1001,110..»